DrugPatentWatch® Litigation and Generic Entry Outlook for Xtandi.
A generic version of XTANDI was approved as enzalutamide by APOTEX on April 22nd, 2022.
Nubeqa aka Darolutamide will be eligible for patent challenges on July 30, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
this is very good news!!
Written by
Scout4answers
To view profiles and participate in discussions please or .
Well Enzalutamide costs in europe a fraction of the USA price something in the range of a few hundred a month. I wonder if it could make sense to cross the ditch to buy a few months supply.
Thanks for mentioning! Everyone is encourage to read about March in Rights…passed with Senator Dole’s name on it. Basically it has to do with the government investing in drug research and then the companies charging large amounts. Prostate cancer men challenged that the government hasn’t implemented this. healthaffairs.org/do/10.137...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.